Interim Report 2020

舜宇光學科技（集團）有限公司 • 2020 中報 11 Management Discussion and Analysis 管理層討論與分析 Optical Instruments For the six months ended 30 June 2020, the revenue from the Optical Instruments business segment was approximately RMB126.5 million, representing an increase of approximately 3.9% compared to the corresponding period of last year. This segment accounted for approximately 0.7% of the Group’s total revenue, compared to approximately 0.8% in the corresponding period of last year. During the period under review, the Group made further efforts in transforming to the role of instrument system solution integrator. The microscopes and intelligent equipment businesses made certain progress. In terms of microscopes business, the Group has completed the R&D of the first global upright near-infrared region-II fluorescence microscopic in vivo imaging system, and it successfully addresses the problem that traditional microscopes cannot directly observe vivo biological tissues. The system combines the near-infrared region-II fluorescence imaging with microtechnology for the first time, realizing the dynamic and real-time imaging and observation of vivo biological samples. The successful R&D of the system not only fills the gap in the international vivo micro-imaging technology, but also provides strong technical support for the world’s basic medical research, clinical medical applications and other fields. In addition, the Group pioneered and mass produced the first domestic 1.25-time apochromatic objective with broadband (400-1,700 nm) and large field of view. The objective can freely observe a large area of vivo samples in the visible light to near- infrared waveband, significantly enhance the coverage area and improve the detecting efficiency of the area array. Furthermore, the Group firstly realised the mass production of the objective with a numerical aperture of 0.8, a field number of 30 mm and high distinguishability (wavefront error<0.085). This objective can meet the high distinguishability imaging needs of customers and achieve large field of view, enhancing imaging efficiency. 光學儀器 截至二零二零年六月三十日止六個月，光學儀 器事業的收入約人民幣 126,500,000 元，較去 年同期增長約 3.9% 。該事業佔本集團的總收入 約 0.7% ，而在去年同期則佔約 0.8% 。 於回顧期內，本集團進一步向儀器系統方案集 成商的角色轉變上作出努力，顯微鏡和智能裝 備兩大業務取得了一定的進展。在顯微鏡業務 方面，本集團完成了全球首款近紅外二區活體 熒光正置顯微影像系統的研發，成功解決了傳 統顯微鏡無法對活體生物組織直接觀測的問 題。該系統首次將近紅外二區熒光成像與顯微 技術相結合，實現了對活體生物樣品的動態、 實時成像與觀測。該系統的成功研發不僅填補 了國際活體顯微顯像的技術空白，也為世界基 礎醫學研究、臨床醫學應用和其他領域提供了 強有力的技術支持。另外，本集團於國內首創 寬波段 (400-1,700nm) 大視場復消色差 1.25 倍 物鏡並實現量產。該物鏡能夠在可見光至近紅 外波段自由觀測大面積活體樣本，大幅提升一 次成像區域，提升面陣探測效率。此外，本集 團於國內率先實現數值孔徑為 0.8 ，視場數為 30mm ，高分辨率（波前誤差＜ 0.085 ）物鏡的 量產。該物鏡能夠滿足客戶高分辨率的成像需 求，並實現大視場角，從而提升成像效率。